. 2012 May;141(5):1303–1314. doi: 10.1378/chest.11-2800

Table 4.

—Meta-analyses of Randomized Controlled Trials of SIT for Treating Allergic Rhinitis

Study/Year	Patients	Allergens	Symptom Scores, SMD (95% CI)	Medication Scores, SMD (95% CI)	Comment
Calderon et al⁴³/2007	2,871 adults	SCIT	−0.73 (−0.97, −0.50)	−0.57 (−0.82, −0.33)	No children included
		Seasonal	I² = 63%	I² = 64%	No fatalities reported
		Seasonal	I² = 63%	I² = 64%	Moderate heterogeneity
Radulovic et al⁴⁴/2010	4,589 adults and children	SLIT	−0.49 (−0.64, −0.34)	−0.32 (−0.43, 0.21)	Considerable heterogeneity despite inclusion of large trials
Radulovic et al⁴⁴/2010	4,589 adults and children	Seasonal and perennial	I² = 81%	I² = 50%
Penagos et al⁴⁵/2006	484 children	SLIT	−0.56 (−1.01, −0.10)	−0.76 (−1.46, −0.06)	Considerable heterogeneity
Penagos et al⁴⁵/2006	484 children	Seasonal and perennial	I² = 81%	I² = 86%	Considerable heterogeneity
Olaguíbel and Alvarez Puebla⁴⁰/2005	232 children	SLIT	−0.44 (−1.22, −0.35)	Not reported	Small numbers
Olaguíbel and Alvarez Puebla⁴⁰/2005	232 children	Seasonal and perennial	I² = Not reported	Not reported	Heterogeneity not reported
Compalati et al⁴¹/2009	382 adults and children	SLIT	−0.95 (−1.77, −0.14)	−1.88 (−3.65, −0.12)	Considerable heterogeneity despite focus on a single allergen
Compalati et al⁴¹/2009	382 adults and children	House dust mite	I² = 92%	I² = 95%
Di Bona et al⁴⁶/2010	2,971 adults and children with rhinitis	SLIT	−0.32 (−0.44, −0.21)	−0.33 (−0.50, −0.16)	Moderate heterogeneity
Di Bona et al⁴⁶/2010	2,971 adults and children with rhinitis	Grass pollen	I² = 56%	I² = 78%	Moderate heterogeneity

See Table 1 and 3 legends for expansion of other abbreviations. (Reproduced with permission from Calderón et al.⁴²)